Cell No. : Cell Name
RCB2227 : JMSU1
update : 2024/04/12
|
| Comment | Human cell line derived from urinary bladder carcinoma. Derived from ascites. |
| Comment from the depositor | |
| Terms and conditions | There is no restriction regarding use for basic researches. In relation to commercial use and use for patent filing, first of all please contact the RIKEN BRC. |
| Remarks | |
| Order Form |
Order Form(C-0005.pdf)
MTA(C-0007.pdf)
MTA(C-0007p.pdf)
|
|
Regarding MTA between user institutions and RIKEN BRC, there are two kinds of MTA, not-for-profit academic purpose (C-XXXX) and for-profit research purpose (C-XXXXp) , depending on the sort of user institutions and the purposes of use. Please use an appropriate MTA(to see). In relation to commercial use and use for patent filing, first of all Please contact RIKEN BRC (cellbank.brc@riken.jp).
|
|
|
Basic information
|
Depositor |
Morita, Tasuo
|
| Originator |
Morita, Tatsuo
|
| Year of deposit |
2002
|
| Another name |
HMSU-1
|
| Animal |
_human
< Mammals
|
| Genus |
Homo
|
| Species |
sapiens
|
| Race |
Japanese
|
| Gender |
Male
|
| Age at sampling |
75 years
|
| Tissue |
bladder, ascites meta
|
| Disease name |
urinary bladder carcinoma
|
| Metastatic ability |
Yes
|
| Metastatic tissue |
lung, liver, bone marrow, lympho node, peritoneum
|
| Classification |
cancer
|
|
Lifespan |
infinite
|
| Morphology |
epithelial-like
|
| Cellosaurus(Expasy) |
CVCL_2081
|
|
| |
deposit info |
lot info |
|
Medium |
Medium List |
|
Culture type |
|
Adherent cells
|
| Culture medium |
|
RPMI1640 + 10% FBS
|
| Antibiotics |
|
Free
|
|
Passage method |
|
0.25% Trypsin
|
Culture information
|
Passage ratio |
|
1 : 8 split
|
| SC frequency |
|
Subculture : 2 times/week
|
| Temperature |
|
37
℃
|
| CO2 concentration |
|
5
%
|
| Freeze medium |
|
Medium + 10% DMSO
|
| Freezing method |
|
Slow freezing
|
| Mycoplasma |
|
(-)
|
| Isozyme |
|
LD, NP
|
| STR(human) |
|
OK
|
| Images |
deposit info | lot info |
|
|
|
| Reference information |
Reference |
0
|
| User's Publication |
4
|
| User's Publication |
|
21582
Schönherr H, Ayaz P, Taylor AM, Casaletto JB, Touré BB, Moustakas DT, Hudson BM, Valverde R, Zhao S, O'Hearn PJ, Foster L, Sharon DA, Garfinkle S, Giordanetto F, Lescarbeau A, Kurukulasuriya R, Gerami-Moayed N, Maglic D, Bruderek K, Naik G, Gunaydin H, Mader MM, Boezio AA, McLean TH, Chen R, Wang Y, Shaw DE, Watters J, Bergstrom DA.
Discovery of lirafugratinib (RLY-4008), a highly selective irreversible small-molecule inhibitor of FGFR2.
Proc Natl Acad Sci U S A
2024
121(6):e2317756121
PubMed ID: 38300868
DOI: 10.1073/pnas.2317756121
|
|
21362
Ando K, Kurashina R, Motoi N, Iizuka T, Inoue M, Maruyama R, Mitani K, Takenobu H, Haruta M, Onuki R, Matsuoka Y, Kamijo T, Kageyama Y.
Positive regulatory loop of platelet-derived growth factor DD-induced STAT3 activation is associated with poor prognosis in advanced urothelial carcinoma.
Biochem Biophys Res Commun
2023
676:165-170
PubMed ID: 37517219
DOI: 10.1016/j.bbrc.2023.07.054
|
|
17934
Ohtsu A, Arai S, Sawada T, Kato M, Maeno Y, Miyazawa Y, Fujizuka Y, Sekine Y, Koike H, Matsui H, Suzuki K.
Fibroblast growth factor receptor inhibitor erdafitinib promotes Mcl-1 degradation and synergistically induces apoptosis with Bcl-xL/Bcl-2 inhibitor in urothelial cancer cells
Biochem Biophys Res Commun
2022
628:76-83
PubMed ID: 36084554
DOI: 10.1016/j.bbrc.2022.08.083
|
|
14224
Aya Kikuchi, Tomoyuki Suzuki, Taisuke Nakazawa, Masateru Iizuka, Ayako Nakayama, Tohru Ozawa, Minoru Kameda, Nobuaki Shindoh, Tadashi Terasaka, Masaaki Hirano, Sadao Kuromitsu
ASP5878, a selective FGFR inhibitor, to treat FGFR3-dependent urothelial cancer with or without chemoresistance
Cancer Science
2017
108:236-242
PubMed ID: 27885740
DOI: 10.1111/cas.13124
|
Back
Top
CELL BANK Website